Results 261 to 270 of about 593,039 (291)
Some of the next articles are maybe not open access.
Clinical and Experimental Dermatology, 1992
The presence of large numbers of moles, atypical in appearance and distribution typifies the atypical mole syndrome. The syndrome may occur in one individual alone or in an autosomal-dominant fashion in his/her family. The presence of this phenotype indicates an increased risk of melanoma, although the risk varies according to the presence or absence ...
openaire +2 more sources
The presence of large numbers of moles, atypical in appearance and distribution typifies the atypical mole syndrome. The syndrome may occur in one individual alone or in an autosomal-dominant fashion in his/her family. The presence of this phenotype indicates an increased risk of melanoma, although the risk varies according to the presence or absence ...
openaire +2 more sources
Current Oncology Reports, 2004
Sophisticated molecular techniques that have recently become available permit analysis of genome-wide changes in gene copy number (DNA) or expression (RNA). These genomic strategies have the potential to transform our view of cancer biology and pathogenesis.
openaire +2 more sources
Sophisticated molecular techniques that have recently become available permit analysis of genome-wide changes in gene copy number (DNA) or expression (RNA). These genomic strategies have the potential to transform our view of cancer biology and pathogenesis.
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2016
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
openaire +2 more sources
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
openaire +2 more sources
Recent developments in the medical and surgical treatment of melanoma
Ca-A Cancer Journal for Clinicians, 2014Ragini R Kudchadkar
exaly